CA2679754C - Substituted heterocycle fused gamma-carbolines synthesis - Google Patents

Substituted heterocycle fused gamma-carbolines synthesis Download PDF

Info

Publication number
CA2679754C
CA2679754C CA2679754A CA2679754A CA2679754C CA 2679754 C CA2679754 C CA 2679754C CA 2679754 A CA2679754 A CA 2679754A CA 2679754 A CA2679754 A CA 2679754A CA 2679754 C CA2679754 C CA 2679754C
Authority
CA
Canada
Prior art keywords
formula
compounds
acid
compound
base
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2679754A
Other languages
English (en)
French (fr)
Other versions
CA2679754A1 (en
Inventor
John Charles Tomesch
Peng Li
Wei Yao
Qiang Zhang
James David Beard
Andrew S. Thompson
Hua Cheng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intra Cellular Therapies Inc
Original Assignee
Intra Cellular Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39759858&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2679754(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intra Cellular Therapies Inc filed Critical Intra Cellular Therapies Inc
Publication of CA2679754A1 publication Critical patent/CA2679754A1/en
Application granted granted Critical
Publication of CA2679754C publication Critical patent/CA2679754C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16Peri-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA2679754A 2007-03-12 2008-03-12 Substituted heterocycle fused gamma-carbolines synthesis Active CA2679754C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90647307P 2007-03-12 2007-03-12
US60/906,473 2007-03-12
PCT/US2008/003340 WO2008112280A1 (en) 2007-03-12 2008-03-12 Substituted heterocycle fused gamma-carbolines synthesis

Publications (2)

Publication Number Publication Date
CA2679754A1 CA2679754A1 (en) 2008-09-18
CA2679754C true CA2679754C (en) 2018-08-07

Family

ID=39759858

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2679754A Active CA2679754C (en) 2007-03-12 2008-03-12 Substituted heterocycle fused gamma-carbolines synthesis

Country Status (12)

Country Link
US (11) US8309722B2 (enExample)
EP (2) EP3663294A1 (enExample)
JP (7) JP5567349B2 (enExample)
KR (7) KR101805914B1 (enExample)
CN (2) CN101796051B (enExample)
AU (5) AU2008226814C1 (enExample)
CA (1) CA2679754C (enExample)
DK (1) DK2134710T3 (enExample)
ES (1) ES2776889T3 (enExample)
IN (1) IN2009DN05670A (enExample)
MX (3) MX394214B (enExample)
WO (1) WO2008112280A1 (enExample)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101805914B1 (ko) 2007-03-12 2017-12-06 인트라-셀룰라 써래피스, 인코퍼레이티드. 치환된 헤테로환 융합 감마-카르볼린 합성
EP2476680B1 (en) 2008-01-11 2014-08-27 Albany Molecular Research, Inc. (1-Azinone)-Substituted Pyridoindoles
PL2262505T3 (pl) 2008-03-12 2015-04-30 Intra Cellular Therapies Inc Podstawione heterocykliczne skondensowane gamma-karboliny w postaci stałej
JP6106361B2 (ja) 2008-05-27 2017-03-29 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. 睡眠障害および他の障害のための方法および組成物
US9107696B2 (en) * 2008-08-06 2015-08-18 Emory University Method of embryo transfer that eliminates transferred air while hormonally inducing implantation and apparatus
US9625475B2 (en) 2008-09-29 2017-04-18 Abbvie Inc. Indole and indoline derivatives and methods of use thereof
TW201018694A (en) 2008-09-29 2010-05-16 Abbott Lab Indole and indoline derivatives and methods of use thereof
US8618299B2 (en) 2009-07-01 2013-12-31 Albany Molecular Research, Inc. Azinone-substituted azapolycycle MCH-1 antagonists, methods of making, and use thereof
JP2012532144A (ja) 2009-07-01 2012-12-13 アルバニー モレキュラー リサーチ, インコーポレイテッド アジノン置換アゼピノ[b]インドールおよびピリド−ピロロ−アゼピンmch−1拮抗薬、ならびにその作製方法および使用
US9073925B2 (en) 2009-07-01 2015-07-07 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
WO2011003007A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
US8993572B2 (en) 2010-04-22 2015-03-31 Intra-Cellular Therapies, Inc. Pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines derivatives and [1,4]oxazino[2,3,4-hi]pyrido[4,3-b]indole derivatives
WO2012088038A2 (en) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline mch-1 antagonists, methods of making, and uses thereof
US8993765B2 (en) 2010-12-21 2015-03-31 Albany Molecular Research, Inc. Tetrahydro-azacarboline MCH-1 antagonists, methods of making, and uses thereof
ES2727815T3 (es) 2012-04-14 2019-10-18 Intra Cellular Therapies Inc Tratamiento del TEPT y de trastornos del control de impulsos
PL2968320T3 (pl) 2013-03-15 2021-05-17 Intra-Cellular Therapies, Inc. Związki organiczne
AU2014360452C1 (en) 2013-12-03 2019-05-16 Intra-Cellular Therapies, Inc. Novel methods
WO2015154030A1 (en) 2014-04-04 2015-10-08 Intra-Cellular Therapies, Inc. Organic compounds
KR20170012210A (ko) 2014-04-04 2017-02-02 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
WO2015191554A1 (en) 2014-06-09 2015-12-17 Intra-Cellular Therapies, Inc. Compounds and methods of use to treat schizophrenia
WO2016057931A1 (en) 2014-10-10 2016-04-14 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
CA2983992A1 (en) 2015-04-30 2016-11-03 The Regents Of The University Of Colorado, A Body Corporate Polycyclic indoline and indolenine compounds
IL309536B2 (en) 2016-01-26 2025-07-01 Intra Cellular Therapies Inc Pharmaceutical preparation for injection containing (Sa10, Rb6)-3-)8-(4-fluorophenoxy)propyl)-b6, 7, 8, 9, 10, 10a- hexahydro-H1- pyrido[3',4' :4,5]pyrrolo[1,2,3 -de]quinoxalin-2(H3)-one
US10688097B2 (en) 2016-03-25 2020-06-23 Intra-Cellular Therapies, Inc. Organic compounds
US11014925B2 (en) 2016-03-28 2021-05-25 Intra-Cellular Therapies, Inc. Co-crystals of 1-(4-fluoro-phenyl)-4-((6bR,1OaS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H- pyrido[3′,4′:4,51_pyrrolo [1,2,3-delqcuinoxalin-8-yl)-butan-1-one with nicotinamide or isonicotinamide
EP3436083A4 (en) 2016-03-28 2019-11-27 Intra-Cellular Therapies, Inc. NOVEL COMPOSITIONS AND METHOD
JP2019513143A (ja) * 2016-03-28 2019-05-23 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. 新規塩類および結晶
HRP20211666T1 (hr) 2016-08-09 2022-02-18 Teva Pharmaceuticals International Gmbh Oblici soli lumateperon ditozilata u krutom stanju
WO2018064465A1 (en) 2016-09-29 2018-04-05 The Regents Of The University Of California Compounds for increasing neural plasticity
JP7013454B2 (ja) 2016-10-12 2022-02-15 イントラ-セルラー・セラピーズ・インコーポレイテッド アモルファス固体分散体
US10961245B2 (en) 2016-12-29 2021-03-30 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines for treatment of central nervous system disorders
US10906906B2 (en) 2016-12-29 2021-02-02 Intra-Cellular Therapies, Inc. Organic compounds
JP7132939B2 (ja) 2017-03-24 2022-09-07 イントラ-セルラー・セラピーズ・インコーポレイテッド 新規組成物および方法
US11292793B2 (en) 2017-04-10 2022-04-05 Dr. Reddy's Laboratories Limited Solid dispersions of amorphous Lumateperone p-Tosylate
US11427587B2 (en) 2017-07-26 2022-08-30 Intra-Cellular Therapies, Inc. Organic compounds
EP3658145A4 (en) 2017-07-26 2021-04-21 Intra-Cellular Therapies, Inc. ORGANIC COMPOUNDS
WO2019067591A1 (en) * 2017-09-26 2019-04-04 Intra-Cellular Therapies, Inc. NEW SALTS AND CRYSTALS
WO2019102240A1 (en) * 2017-11-27 2019-05-31 Egis Gyógyszergyár Zrt. Method for the manufacture of lumateperone and its salts
EP3765021A4 (en) 2018-03-16 2022-03-09 Intra-Cellular Therapies, Inc. NOVEL PROCESSES
WO2019183546A1 (en) 2018-03-23 2019-09-26 Intra-Cellular Therapies, Inc. Organic compounds
BR112020019119A2 (pt) 2018-03-23 2021-01-12 Intra-Cellular Therapies, Inc. Compostos orgânicos
IL279195B1 (en) 2018-06-06 2025-08-01 Intra Cellular Therapies Inc A method of making bis-tosylate salt of lumateparone
CA3102948A1 (en) 2018-06-08 2019-12-12 Intra-Cellular Therapies, Inc. Novel methods
KR102778034B1 (ko) * 2018-06-11 2025-03-12 인트라-셀룰라 써래피스, 인코퍼레이티드. 치환된 헤테로환 융합 감마-카르볼린 합성
CN112585690B (zh) 2018-06-21 2025-04-15 阿奎斯蒂弗医疗股份有限公司 用于制作含有药物活性物质的个性化个体单位剂量的系统和方法
BR112021002298A2 (pt) 2018-08-13 2021-05-04 F. Hoffmann-La Roche Ag compostos heterocíclicos como inibidores da monoacilglicerol lipase
JP2022500362A (ja) 2018-08-29 2022-01-04 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. 新規組成物および方法
WO2020047408A1 (en) 2018-08-31 2020-03-05 Intra-Cellular Therapies, Inc. Novel methods
CN112584837A (zh) 2018-08-31 2021-03-30 细胞内治疗公司 新方法
WO2020051317A1 (en) 2018-09-07 2020-03-12 Aquestive Therapeutics, Inc. Oral film compositions and dosage forms having precise active dissolution profiles
EP3887374A2 (en) 2018-11-27 2021-10-06 Teva Pharmaceuticals International GmbH Solid state forms of lumateperone salts and processes for preparation of lumateperone and salts thereof
US12297200B2 (en) 2018-12-17 2025-05-13 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines synthesis
CN113423568A (zh) 2018-12-17 2021-09-21 细胞内治疗公司 有机化合物
US12358916B2 (en) 2018-12-17 2025-07-15 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines synthesis
US12331052B2 (en) 2018-12-21 2025-06-17 Intra-Cellular Therapies, Inc. Organic compounds
EP3897643B1 (en) 2018-12-21 2023-11-15 Intra-Cellular Therapies, Inc. A pyridopyrroloquinoxaline compound and its medical use
CA3130770A1 (en) 2019-02-27 2020-09-03 The Regents Of The University Of California Azepino-indoles and other heterocycles for treating brain disorders
MX2022000143A (es) 2019-07-07 2022-02-17 Intra Cellular Therapies Inc Metodos novedosos.
EP4034119A4 (en) 2019-09-25 2023-10-18 Intra-Cellular Therapies, Inc. NOVEL METHODS
AU2020373100A1 (en) 2019-11-01 2022-05-19 Aquestive Therapeutics, Inc. Prodrug compositions and methods of treatment
BR112022008784A2 (pt) 2019-11-14 2022-07-26 Aquestive Therapeutics Inc Composições multimodais e métodos de tratamento
CN110698474B (zh) * 2019-11-14 2021-11-02 福州大学 一种α位取代四氢-γ-咔啉类化合物及其制备方法和应用
JP7261942B2 (ja) 2019-12-11 2023-04-20 イントラ-セルラー・セラピーズ・インコーポレイテッド 有機化合物
WO2021127572A1 (en) 2019-12-19 2021-06-24 Intra-Cellular Therapies, Inc. Methods of schizophrenia treatment
CN112062767B (zh) * 2020-10-20 2022-03-11 杭州科巢生物科技有限公司 一种卢美哌隆的制备方法及其中间体
WO2022155544A1 (en) 2021-01-15 2022-07-21 Aquestive Therapeutics, Inc. Prodrug compositions and methods of treatment
WO2022192476A1 (en) 2021-03-09 2022-09-15 Aquestive Therapeutics, Inc. Dosage forms having equivalent biocomparable profiles
CN113024554B (zh) * 2021-03-24 2023-03-14 上海法默生物科技有限公司 一种卢美哌隆中间体的制备方法
CN114105980B (zh) * 2021-12-13 2024-04-16 南方科技大学坪山生物医药研究院 卢美哌隆中间体化合物的制备方法及卢美哌隆中间体化合物
CN114105985B (zh) * 2021-12-13 2024-04-16 南方科技大学坪山生物医药研究院 不对称氢化构建卢美哌隆中间体的方法及卢美哌隆中间体
TW202333668A (zh) 2021-12-15 2023-09-01 美商德利克斯醫療公司 經苯氧基及苄氧基取代之精神成形素(psychoplastogen)及其用途
US12414948B2 (en) 2022-05-18 2025-09-16 Intra-Cellular Therapies, Inc. Methods
EP4642458A1 (en) 2022-12-30 2025-11-05 Intra-Cellular Therapies, Inc. Heterocycle fused gamma-carbolines acting on the serotonine 5-ht2a receptor
WO2024173901A1 (en) 2023-02-17 2024-08-22 Intra-Cellular Therapies, Inc. Lumateperone and derivatives thereof for modulating the nervous system
WO2025223504A1 (zh) * 2024-04-26 2025-10-30 浙江奥翔药业股份有限公司 卢美哌隆中间体及其制备方法
US20250352469A1 (en) 2024-05-16 2025-11-20 Intra-Cellular Therapies, Inc. Novel compositions, devices, and methods
CN119912455B (zh) * 2025-01-22 2025-09-23 成都臻拓医药科技有限公司 一种卢美哌隆中间体化合物的制备方法

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6713A (en) 1849-09-11 Hobse-poweb
US471A (en) 1837-11-20 Mode of
US39680A (en) 1863-08-25 Improvement in machines for breaking and cleaning flax
US38679A (en) 1863-05-26 Improvement in water-elevators
US2490813A (en) 1944-11-29 1949-12-13 Standard Oil Co Continuous process for making aryl amines
US3299078A (en) 1962-10-01 1967-01-17 Smith Kline French Lab Pyrido [3', 4': 4, 5] pyrrolo [3, 2, 1-hi] indoles and-[3, 2, 1-ij] quinolines
US3813392A (en) 1969-06-09 1974-05-28 J Sellstedt Pyrrolo(1,2,3-alpha epsilon)quinoxalin-2(3h)-ones and related compounds
US4238607A (en) 1972-06-19 1980-12-09 Endo Laboratories Inc. Pyridopyrrolo benzheterocycles
US4115577A (en) 1972-06-19 1978-09-19 Endo Laboratories, Inc. Pyridopyrrolobenzheterocycles
US3914421A (en) 1972-06-19 1975-10-21 Endo Lab Pyridopyrrolobenzheterocycles for combatting depression
US4183936A (en) 1972-06-19 1980-01-15 Endo Laboratories, Inc. Pyridopyrrolobenzheterocycles
US4219550A (en) 1978-11-09 1980-08-26 E. I. Du Pont De Nemours And Company Cis- and trans- octahydropyridopyrrolobenzheterocycles
US4522944A (en) 1982-12-23 1985-06-11 Erba Farmitalia Carboxamido-derivatives of 5H-1,3,4-thiadiazolo[3,2-a]pyrimidines, compositions and use
EP0238059B1 (en) 1986-03-19 1993-06-16 Kumiai Chemical Industry Co., Ltd. 5H-1,3,4-Thiazole[3,2-a]pyrimidin-5-one derivatives and fungicidal compositions containing the same
ES2058069T3 (es) 1986-04-07 1994-11-01 Kumiai Chemical Industry Co Derivados de 5h-1,3,4-tiadiazolo-(3,2-a)-pirimidin-5-ona y nuevo compuesto fungicida agricola-horticola que contiene dicho derivado.
US5576460A (en) 1994-07-27 1996-11-19 Massachusetts Institute Of Technology Preparation of arylamines
US5648542A (en) 1996-02-29 1997-07-15 Xerox Corporation Arylamine processes
US5648539A (en) 1996-02-29 1997-07-15 Xerox Corporation Low temperature arylamine processes
US5654482A (en) 1996-02-29 1997-08-05 Xerox Corporation Triarylamine processes
US5847166A (en) 1996-10-10 1998-12-08 Massachusetts Institute Of Technology Synthesis of aryl ethers
US5705697A (en) 1997-01-30 1998-01-06 Xerox Corporation Arylamine processes
US5723671A (en) 1997-01-30 1998-03-03 Xerox Corporation Arylamine processes
US5723669A (en) 1997-01-30 1998-03-03 Xerox Corporation Arylamine processes
US6323366B1 (en) 1997-07-29 2001-11-27 Massachusetts Institute Of Technology Arylamine synthesis
GB2328686B (en) 1997-08-25 2001-09-26 Sankio Chemical Co Ltd Method for producing arylamine
US6395939B1 (en) 1997-10-06 2002-05-28 Massachusetts Institute Of Technology Diaryl ether condensation reactions
EP1058678B1 (en) 1998-02-26 2002-12-11 Massachusetts Institute of Technology Metal-catalyzed arylations and vinylations of hydrazines, hydrazones, hydroxylamines and oximes
US6235936B1 (en) 1998-02-26 2001-05-22 Massachusetts Institute Of Technology Metal-catalyzed arylations of hydrazines, hydrazones, and related substrates
US5902901A (en) 1998-05-07 1999-05-11 Xerox Corporation Arylamine processes
US6307087B1 (en) 1998-07-10 2001-10-23 Massachusetts Institute Of Technology Ligands for metals and improved metal-catalyzed processes based thereon
US7223879B2 (en) 1998-07-10 2007-05-29 Massachusetts Institute Of Technology Ligands for metals and improved metal-catalyzed processes based thereon
JP5035813B2 (ja) 1998-07-10 2012-09-26 マサチューセッツ インスティテュート オブ テクノロジー 金属用のリガンドおよびそれらに基づいて改善された金属触媒法
US6395916B1 (en) 1998-07-10 2002-05-28 Massachusetts Institute Of Technology Ligands for metals and improved metal-catalyzed processes based thereon
US20010008942A1 (en) 1998-12-08 2001-07-19 Buchwald Stephen L. Synthesis of aryl ethers
PE20010052A1 (es) 1999-04-23 2001-01-27 Upjohn Co Compuestos de azepinindol tetraciclico como agonistas o antagonistas del receptor de 5-ht
US6407092B1 (en) 1999-04-23 2002-06-18 Pharmacia & Upjohn Company Tetracyclic azepinoindole compounds
US6713471B1 (en) 1999-06-15 2004-03-30 Bristol-Myers Squibb Pharma Company Substituted heterocycle fused gamma-carbolines
US7071186B2 (en) * 1999-06-15 2006-07-04 Bristol-Myers Squibb Pharma Co. Substituted heterocycle fused gamma-carbolines
CN1370176A (zh) 1999-06-15 2002-09-18 布里斯托尔-迈尔斯斯奎布药品公司 取代的杂环稠合γ-咔啉
US6541639B2 (en) 2000-07-26 2003-04-01 Bristol-Myers Squibb Pharma Company Efficient ligand-mediated Ullmann coupling of anilines and azoles
US6849619B2 (en) 2000-12-20 2005-02-01 Bristol-Myers Squibb Company Substituted pyridoindoles as serotonin agonists and antagonists
BR0116429A (pt) 2000-12-20 2006-05-09 Bristol Myers Squibb Co piridoindóis substituìdos como agonistas e antagonistas da serotonina
CN1854128B (zh) 2001-04-24 2012-05-16 麻省理工学院 铜-催化的碳-杂原子键和碳-碳键的形成
CA2453537A1 (en) * 2001-08-08 2003-02-20 Pharmacia & Upjohn Company Therapeutic 1h-pyrido¬4,3-b|indoles
KR20050032107A (ko) 2002-08-02 2005-04-06 메사추세츠 인스티튜트 오브 테크놀로지 구리를 촉매로 한 탄소-헤테로원자 결합 및 탄소-탄소결합 형성방법
US7223870B2 (en) 2002-11-01 2007-05-29 Pfizer Inc. Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction
US7109339B2 (en) * 2002-12-19 2006-09-19 Bristol-Myers Squibb Company Substituted tricyclic gamma-carbolines as serotonin receptor agonists and antagonists
JP2005259113A (ja) 2004-02-12 2005-09-22 Ricoh Co Ltd プロセス編集装置、プロセス管理装置、プロセス編集プログラム、プロセス管理プログラム、記録媒体、プロセス編集方法及びプロセス管理方法
US7592454B2 (en) * 2004-04-14 2009-09-22 Bristol-Myers Squibb Company Substituted hexahydro-pyridoindole derivatives as serotonin receptor agonists and antagonists
MX2007006896A (es) * 2004-12-15 2007-06-26 Hoffmann La Roche Fenil-metanonas bi- y triciclicas sustituidas como inhibidores del transportador 1 de glicina (glyt-1) para el tratamiento de la enfermedad de alzheimer.
KR101805914B1 (ko) * 2007-03-12 2017-12-06 인트라-셀룰라 써래피스, 인코퍼레이티드. 치환된 헤테로환 융합 감마-카르볼린 합성
PL2262505T3 (pl) 2008-03-12 2015-04-30 Intra Cellular Therapies Inc Podstawione heterocykliczne skondensowane gamma-karboliny w postaci stałej
JP6106361B2 (ja) 2008-05-27 2017-03-29 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. 睡眠障害および他の障害のための方法および組成物
US8309772B2 (en) 2008-07-31 2012-11-13 Celanese International Corporation Tunable catalyst gas phase hydrogenation of carboxylic acids
US8993572B2 (en) * 2010-04-22 2015-03-31 Intra-Cellular Therapies, Inc. Pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines derivatives and [1,4]oxazino[2,3,4-hi]pyrido[4,3-b]indole derivatives
ES2727815T3 (es) 2012-04-14 2019-10-18 Intra Cellular Therapies Inc Tratamiento del TEPT y de trastornos del control de impulsos
PL2968320T3 (pl) 2013-03-15 2021-05-17 Intra-Cellular Therapies, Inc. Związki organiczne
AU2014360452C1 (en) 2013-12-03 2019-05-16 Intra-Cellular Therapies, Inc. Novel methods
KR20170012210A (ko) 2014-04-04 2017-02-02 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
US10688097B2 (en) 2016-03-25 2020-06-23 Intra-Cellular Therapies, Inc. Organic compounds
WO2019102240A1 (en) 2017-11-27 2019-05-31 Egis Gyógyszergyár Zrt. Method for the manufacture of lumateperone and its salts

Also Published As

Publication number Publication date
EP3663294A1 (en) 2020-06-10
MX2020001497A (es) 2020-03-12
US20180044337A1 (en) 2018-02-15
DK2134710T3 (da) 2020-05-18
EP2134710B1 (en) 2020-02-12
EP2134710A1 (en) 2009-12-23
US20250101022A1 (en) 2025-03-27
AU2008226814C1 (en) 2014-11-20
AU2014203483B2 (en) 2016-06-30
US20200115380A1 (en) 2020-04-16
US10597395B2 (en) 2020-03-24
AU2019229334A1 (en) 2019-10-03
US20100113781A1 (en) 2010-05-06
EP2134710A4 (en) 2011-09-28
CN101796051A (zh) 2010-08-04
KR101981840B1 (ko) 2019-05-23
JP5567349B2 (ja) 2014-08-06
MX394214B (es) 2025-03-24
US20220332716A1 (en) 2022-10-20
KR101999300B1 (ko) 2019-07-12
KR20190053975A (ko) 2019-05-20
US20140364609A1 (en) 2014-12-11
KR102065319B1 (ko) 2020-01-10
US20160194326A1 (en) 2016-07-07
AU2019229334B2 (en) 2020-09-17
AU2018201818B2 (en) 2019-06-20
KR20210038731A (ko) 2021-04-07
AU2016234905A1 (en) 2016-10-20
US10464938B2 (en) 2019-11-05
JP2010521464A (ja) 2010-06-24
KR102238390B1 (ko) 2021-04-08
US20190292185A1 (en) 2019-09-26
AU2008226814A1 (en) 2008-09-18
US8779139B2 (en) 2014-07-15
JP6231151B2 (ja) 2017-11-15
JP6522710B2 (ja) 2019-05-29
KR102372149B1 (ko) 2022-03-07
US9315504B2 (en) 2016-04-19
JP2022180440A (ja) 2022-12-06
JP6773837B2 (ja) 2020-10-21
AU2018201818A1 (en) 2018-04-05
AU2016234905B2 (en) 2018-03-29
US11066407B2 (en) 2021-07-20
US9751883B2 (en) 2017-09-05
IN2009DN05670A (enExample) 2015-07-24
JP2016155849A (ja) 2016-09-01
ES2776889T3 (es) 2020-08-03
KR20180074802A (ko) 2018-07-03
JP2014208676A (ja) 2014-11-06
KR101805914B1 (ko) 2017-12-06
US20130046097A1 (en) 2013-02-21
US12139490B2 (en) 2024-11-12
WO2008112280A1 (en) 2008-09-18
MX2022008904A (es) 2022-08-16
MX2009009773A (es) 2009-12-16
US11407751B2 (en) 2022-08-09
KR102107954B1 (ko) 2020-05-07
AU2014203483A1 (en) 2014-07-17
US20200087305A1 (en) 2020-03-19
KR20200047755A (ko) 2020-05-07
JP2018035189A (ja) 2018-03-08
JP2019147819A (ja) 2019-09-05
CA2679754A1 (en) 2008-09-18
AU2008226814B2 (en) 2014-03-27
KR20100014428A (ko) 2010-02-10
JP5918306B2 (ja) 2016-05-18
KR20150140397A (ko) 2015-12-15
CN103626766B (zh) 2017-06-09
CN103626766A (zh) 2014-03-12
KR20190083009A (ko) 2019-07-10
CN101796051B (zh) 2013-11-06
JP2021006559A (ja) 2021-01-21
US20190218219A1 (en) 2019-07-18
US8309722B2 (en) 2012-11-13
US10221176B2 (en) 2019-03-05

Similar Documents

Publication Publication Date Title
CA2679754C (en) Substituted heterocycle fused gamma-carbolines synthesis
HK40031914A (en) Substituted heterocycle fused gamma-carbolines synthesis
HK1139932A (en) Substituted heterocycle fused gamma-carbolines synthesis
HK1139932B (en) Substituted heterocycle fused gamma-carbolines synthesis

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130311